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2Abstract
Beta-secretase (BACE1), the enzyme responsible for the first and rate-limiting step in the production of
amyloid-beta peptides, is an attractive target for the treatment of Alzheimer's disease. In this study, we
report the application of the de novo fragment-based molecular design program SPROUT to the
discovery of a series of non-peptide BACE1 inhibitors based upon a biphenylacetamide scaffold. The
binding affinity of molecules based upon this designed molecular scaffold was increased from an initial
BACE1 IC50 RI  ȝ0 WR  ȝ0 IROORZLQJ WKH V\QWKHVLV RI D OLEUDU\ RI RSWLPL]HG OLJDQGV ZKRVH
structures were refined using the recently developed SPROUT-HitOpt software. Although a number of
inhibitors were found to exhibit cellular toxicity, one compound in the series was found to have useful
BACE1 inhibitory activity in a cellular assay with minimal cellular toxicity.
This work demonstrates the power of an in silico fragment-based molecular design approach in the
discovery of novel BACE1 inhibitors.
3Introduction
Alzheimer’s disease (AD) is the most common neurodegenerative disease which currently affects
more than 30 million people worldwide.1 The number of AD patients is expected to increase
significantly with the ageing human population. While current approved treatments using
acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists provide
symptomatic relief for AD patients, there is a lack of effective therapy targeting the underlying
pathophysiology of AD.2
The accumulation of amyloid-E peptide (AE) to form the extracellular senile or amyloid plaques is
widely accepted to play a central role in the pathogenesis of AD.3 According to the amyloid cascade
hypothesis,4 AE is generated through the sequential proteolytic cleavage of the amyloid precursor
protein (APP) catalyzed by the EDQGȖVHFUHWDVHV UHVSHFWLYHO\5 Since E-secretase is responsible for
the first and rate-limiting step in the formation of AE, it represents an attractive therapeutic target to halt
the progression of this debilitating disease.
E-Site APP cleaving enzyme 1 (BACE1) is responsible for E-secretase activity in vivo.6 A type I
transmembrane protein, BACE1 belongs to the family of pepsin-like human aspartyl proteases,
characterized by a single transmembrane domain. With the catalytic site located on the lumenal side of
the membrane, BACE1 processes the substrate APP at Met671-Asp672 (APP770 numbering) to release
soluble sAPPE 7KH PHPEUDQHERXQG IUDJPHQW & LV WKHQ SURFHVVHG E\ ȖVHFUHWDVH WR JHQHUDWH WKH
amyloidogenic species AE.3, 4, 7 Since the first X-ray crystal structures of BACE1 were reported in
1999,6, 8, 9 numerous efforts have been made in developing novel and potent inhibitors of BACE1.
In an analogous fashion to the initial development of HIV protease inhibitors in the 1990s,10 the
development of BACE1 inhibitors has primarily focused on substrate-based polypeptides with a non-
cleavable transition-state isostere replacing the scissile amide bond. Due to the relatively complex
structure of the substrate and the hydrophobic nature of the BACE1 active site, the majority of the early
BACE1 inhibitors were characterized by high molecular weights and complex motifs that are lacking in
4drug-like properties.11 More recently, the application of high-throughput screening approaches has led to
the identification of non-peptide BACE1 inhibitors.12-14 A complementary strategy for BACE1 inhibitor
discovery is the application of computer-aided methods to design small-molecule non-peptidic
inhibitors using X-ray crystallographic structures of BACE1.
Computational structure-based molecular design is a strong research tool in medicinal chemistry and
chemical biology, and such methods are gaining popularity both in early-stage hit discovery and in
establishing structure-activity relationships (SAR) during lead optimization stages. The utility of one
such approach, virtual high-throughput screening, in the discovery of BACE1 inhibitors has recently
been demonstrated.15-18 A powerful alternative ligand identification strategy is the use of in silico
fragment-based molecular design which, to our knowledge, has not been applied to the discovery of
BACE1 inhibitors. In this approach, using an X-ray crystal structure of the target enzyme, new potential
ligand structures are constructed de novo, via the precise docking of molecular fragments into chosen
regions of the targeted site. These fragments are then joined together in ways dictated by the user to
yield synthetically approachable ligand scaffolds which are predicted to show good affinity for the
target enzyme.19-21 Here, we present the studies of a new BACE1 inhibitor scaffold designed using the
de novo molecular design program SPROUT.22, 23 A library of structural analogs of the initial designed
skeleton was synthesized and tested against recombinant BACE1. SAR analysis and ligand optimization
of this library of compounds were achieved using hit optimization software SPROUT-HitOpt.
5Results and Discussion
De novo ligand design
We have previously described the application of the de novo molecular design program SPROUT to
the production of a number of enzyme inhibitors and receptor antagonists.19-21 In order to aid the
generation of potent BACE1 inhibitors using SPROUT, the crystal structure of BACE1 co-crystallized
with inhibitor OM00-3 reported by Tang and co-workers was used (PDB code 1M4H; 2.1 Å).24 A
simple non-peptidic ligand scaffold was constructed using SPROUT by joining small fragments docked
into selected individual target sites with spacer templates consisting of six-membered aromatic rings
(Figure 1). The proposed mode of inhibitory action of the designed scaffold was to obstruct the binding
of the substrate APP by blocking its entry into the binding pocket. During planning for the synthesis of
molecules corresponding to the designed ligand scaffold, we decided, for simplicity, to place methylene
units at the three points linking the fragments (marked ‘X’, ‘Y’, and ‘Z’ in Figure 1(b)). It should be
noted that other substituents at the ‘Z’ position of the designed ligand scaffold, including C=O
(producing an amide) and SO2 (producing a sulfonamide) were considered as part of the design process
and were predicted to bind with similar affinity as for the amino variants (Z = CH2). However, in light
of the rather hydrophobic nature of the designed scaffolds, we decided to concentrate on the amines as
these were anticipated to have enhanced aqueous solubility compared to the amide and sulfonamide
variants. This revealed our initial target as amine 1 (Figure 2, shown bound in BACE1 as the
ammonium form as anticipated to predominate under physiological conditions and is located near to the
surface of the protein and exposed to solvent). This designed molecular scaffold was synthesized, and
tested in an in vitro BACE1 activity assay using a quenched fluorescent peptide substrate analog based
on the Swedish mutant APP sequence (SEVNLĻDAEFK).25 25 nM recombinant BACE1 (R&D
Systems, Minneapolis, USA) was pre-incubated with inhibitor compounds for 30 mins before addition
of substrate analog (FAM-SEVNLDAEFK-TAMRA (5 PM) and kinetic measurement of substrate
cleavage by determination of the increase in relative fluorescence units (RFU) compared to controls
6(further details in the Supporting Information). Compound 1 was found to display a modest affinity
against BACE1, with an IC50 of 323 PM (Table 1).
(a) (b)
(c) (d)
Figure 1. De novo design of biphenylacetamide inhibitor 1 in the BACE1 binding pocket (PDB
1M4H). (a) Fragments docked into selected individual target sites, (b) fragments joined to yield
complete ligand scaffold, (c) proposed binding mode of 1 (magenta) with key residues labeled (orange);
and (d) proposed binding mode of 1 with surface of the binding pocket.
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7Figure 2. Schematic showing the proposed interactions of inhibitor 1 (shown in ionic form) with
BACE1.
SAR study
To effectively probe the essential features of compound 1 required for BACE1 inhibition, we prepared
structural analogs of 1 that possessed different functional groups and flexible chain lengths in an attempt
to establish an SAR profile, and to probe the proposed binding mode of the inhibitor. As illustrated in
Figure 2, the ligand was designed to make important H-bond contacts with residues Asn37 and Ile126,
and consequently occupying the deep binding pocket proximal to these residues. The introduction of
different flexible chain lengths in the R1 portion of the inhibitor (Table 1, compounds 2-4) would alter
the geometry of the designed molecule, and was predicted not to bind according to our model (see
Supporting Information for predicted binding scores of selected compounds). We also anticipated that
functional group alterations would render the designed scaffold inactive (Table 1, compounds 5-6).
Biological assay data as listed in Table 1 agreed well with our model predictions, and support the
presence of the amine function in compound 1 as being important for inhibition of BACE1.
Table 1. Analogs of compound 1 synthesized to probe the essential features for BACE1 inhibition
8Compound R1 Inhibition at 100 PM (%)b
1
a 35.6±1.7
2 n.i.c
3 n.i.
4 n.i.
5 15.2±1.5
6 n.i.
a Formulated as the trifluoroacetate salt; b Inhibition of BACE1 activity measured as a percentage of
the control activity in an in vitro BACE1 activity assay (see text). Values shown are mean ± SEM, n
c no inhibition.
Having established one of the important features of 1 required for the inhibition of BACE1, we strived
to enhance the binding affinity of the designed skeleton through the introduction of additional functional
groups by examining our in silico model. First, we observed that while the central aromatic ring of the
biaryl system was acting as a spacer, its orientation was in close proximity to the catalytic aspartate
residues, Asp32 and Asp228. Introduction of substituents bearing H-bond donor groups on this aromatic
ring might form favorable H-bond interactions with the side-chains of these catalytic aspartate residues.
Therefore, we synthesized both the ortho-hydroxy (7) and the meta-hydroxy (8) analogs to test our
hypothesis. However, this proposed alteration did not show significant differences in the inhibition of
BACE1 (Table 2).
Next, we investigated the availability of additional sub-pockets located near the ligand binding
regions proposed. The S1’ pocket of the enzyme could be filled with substituents stemming from the
9alpha-C position between the biaryl system and the amide scaffold (‘X’ position in Figure 1(b)). Several
analogs with different branch chains at the alpha-C position were synthesized and assayed against
BACE1. The trend in the BACE1 IC50 values clearly suggested that the larger the branch chain was at
this alpha-C position, the higher the affinity was towards BACE1, with compounds containing the
isopropyl (11) and benzyl (12) branch chains achieving a 10- to 12-fold increase in potency compared to
1, respectively. Compound 12, in particular, attained a BACE1 IC50 of 26.9 PM (Table 2).
Table 2. Analogs of compound 1 with enhanced inhibition of BACE1
Compound R1 R2 Inhibition at 100 PM (%) IC50 (PM)
1 H H 35.6±1.7 323±5
7 2-OH H 42.5±0.6 >100
8 3-OH H 28.1±3.3 >100
9 3-F Me 51.7±2.7 77.1±7.5
10 3-F
Me
(pure R-isomer)
55.5±1.6 85.7±11.8
11 H iPr 66.1±2.2 33.5±4.8
12 H CH2Ph 101.5±0.0 26.9±4.7
Further optimization using SPROUT-HitOpt
Very recently, we have developed a variant of the de novo molecular design software SPROUT,
SPROUT-HitOpt, to assist ligand optimization. The aim of this software is to modify the structure of a
known ligand and generate variants predicted to display enhanced binding affinity towards the target
enzyme, by fulfilling additional H-bond target sites and/or hydrophobic pockets. A particular feature of
this software is that the optimization process is performed using part of the known ligand as a core
10
structure, in which functional groups are identified as points of extension. Extension from this core
structure is achieved by connecting the identified functional groups to a library of commercially
available starting materials, using connection rules defined in a synthetic chemistry knowledge base.
This program was recently reported to have successfully optimized inhibitors of the anti-malarial target
Plasmodium falciparum dihydroorotate dehydrogenase.20
Since the terminal ring of the biaryl system of inhibitor 1 was docked into a hydrophobic site near
Phe108 and Trp115, we envisaged that more extensive occupancy of this hydrophobic site by extending
deeper into the pocket, or the introduction of additional hydrophobic substituents, would maximize the
potential of this binding pocket. Therefore, we decided to utilize SPROUT-HitOpt to perform a
thorough exploration of the available binding regions proximal to this hydrophobic site, and to improve
the predicted binding affinity of 1. Using 13 as the core structure for SPROUT-HitOpt extension and an
in silico library of commercially available aryl boronic acids (Scheme 1), compound 14, with a 10-fold
increase in predicted binding affinity compared to inhibitor 1, was identified as one of the best
optimized candidates out of 174 structures generated (Figure 3). Biological assay results suggested that
compound 14 had an increased binding affinity towards BACE1 compared to inhibitor 1, attaining an
IC50YDOXHRIȝ0Table 3).
Scheme 1. SPROUT-HitOpt core extension to optimize the terminal aromatic ring of 1
(a) (b)
11
Figure 3. The optimized candidate structure 14 (pink), designed using SPROUT-HitOpt, overlaid
with the predicted binding pose of 1 (magenta). (a) Proposed binding mode of 14 (pink) with key
residues labeled (orange); and (b) proposed binding mode of 14 with surface of the binding pocket.
Following the improved BACE1 binding affinity of 14 through increasing hydrophobicity of the
terminal aromatic ring, we decided to assess the effects of different hydrophobic substituents on BACE1
inhibition. Whereas the pentafluorophenyl analog (15) was found to be slightly less potent than 14, the
3-(trifluoromethyl)phenyl analog (16), despite possessing only one CF3 group, exhibited similar
inhibition of BACE1 as compared to 14. Furthermore, we prepared compound 17 to investigate the
importance of hydrophobic substituents on the terminal phenyl ring for binding to BACE1. Compound
17 failed to reach an IC50 YDOXH EHORZ  ȝ0 IRU ZKLFK ZH SURSRVH WKH GLIIHUHQFH ZDV PDLQO\
attributed to the presence of the polar phenolic moiety (Table 3).
The most potent of our compounds, compound 12 attained an IC50 of 26.9 PM under our assay
conditions. This is relatively high compared to other published (GSK188909)25 and commercially
available BACE inhibitors (E-secretase inhibitor IV, Calbiochem, Nottingham, UK) that have IC50s in
the nM range.
G34
T72
D228
D32
F108
W115
N37
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Table 3. Analogs of inhibitor 1 designed to increase hydrophobicity of the terminal phenyl ring of
the biaryl scaffold
Compound Ar Inhibition at 100 PM (%) IC50 (PM)
1 Ph 35.6±1.7 323±5
14 3,5-(CF3)2C6H3 80.6±2.3 63.9±7.2
15 C6F5 51.8±8.4 101±15.7
16 3-(CF3)C6H4 60.7±2.2 58.9±9.0
17 4-(OH)C6H4 41.3±3.5 >100
Compound specificity: BACE2 inhibition
To test the specificity of the compounds against other related proteases, their activity against BACE2
was also measured in the in vitro assay. BACE2 is also a type I transmembrane aspartyl protease whose
amino acid sequence is 45% identical and 75% similar to BACE1.26 The assay conditions used were
identical to those for BACE1. The results indicated that all of the compounds tested showed at least a
two-fold selectivity for BACE1 over BACE2 except for compounds 12 and 14 (Table 4). The
specificity of our compounds for BACE1 over BACE2 suggests that they will have limited effects on
other structurally related proteases.
Table 4. Relative inhibition of BACE1 and BACE2.
Compound
BACE1
IC50 (PM)
BACE2
IC50 (PM)
1 323±5 >1000
13
9 77.1±7.5 207.2±31.2
10 85.7±11.8 193.8±34.1
11 33.5±4.8 100.5±4.1
12 26.9±4.7 21.0±2.37
14 63.9±7.2 33.2±12.0
15 101±15.7 245.9±34.9
16 58.9±9.0 319.3±34.9
22 63.3±9.1 >1000
Values shown are mean ± SEM, n
Compound toxicity assay and cellular BACE1 inhibition
To assess the potential of this series of de novo designed inhibitors for further development, we used
mammalian cells to assess compound toxicity and cellular BACE1 inhibition. Compounds were
screened for toxicity using the cell viability MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay to determine the percentage of viable cells remaining following compound incubation at
a concentration of 100 PM over a 24-hour period. Compounds that induced a loss of greater than 50% in
cell viability were not tested further for cellular BACE1 inhibition. Compounds that retained cell
viability of 50% or greater at 100 PM were tested on human embryonic kidney (HEK 293) cells stably
expressing BACE1 and wild type human APP that was N-terminally tagged with alkaline phosphatase
(AP-APP) to determine potential BACE1 inhibitory activity. The release of soluble N-terminal sAP-
APP fragments into the media, was determined by measuring the resulting alkaline phosphatase activity
of conditioned media samples taken after the incubation. Inhibition of BACE1 would display a decrease
in the alkaline phosphatase activity of conditioned media compared to control levels. The alkaline
phosphatase activity following compound incubation was expressed as a percentage of the activity in the
appropriate control sample.
14
Many of the changes introduced to the middle aromatic ring of the biaryl scaffold, and also the
addition of branch chains at the alpha-C position, rendered the compounds very toxic (compounds 7-12,
Table 5). In the collection of inhibitors which possessed a terminal phenyl ring with hydrophobic
substituents, compound 14, containing two CF3 groups, was shown to be highly toxic, whereas the
pentafluorophenyl (15) and 3-(trifluoromethyl)phenyl (16) analogs were less toxic. The primary amine
of this series of inhibitors, which, from our earlier studies appeared to be important for BACE1
inhibition, also appeared to contribute to cell toxicity. A comparison between the percentage cell
viability of 1 to that of 5 and 6 revealed that compounds without the primary amine, although inactive
WRZDUGV%$&(ZHUHPXFKOHVVWR[LFDWȝ0,QWULJXHGE\WKLVREVHUYDWLRQZHGHFLGHGWRIXUWKHU
investigate whether the hydrophobic substituents on the terminal phenyl ring of the biaryl scaffold were
partially responsible for the toxicity of compounds 14-16. Analogs 18-20, the corresponding analogs of
14-16 without the primary amine, were assessed. Consistent with our conclusions from the SAR study,
analogs 18-20 were shown to be inactive towards BACE1 but compound toxicity was decreased, with
the exception of analog 20 (we suspected that this discrepancy might be owing to the low solubility of
this compound). It is, however, evident that the hydrophobic substituents on the terminal phenyl ring,
including the bis-(trifluoromethyl)phenyl and the pentafluorophenyl scaffolds, were accountable for a
certain level of toxicity in cells, as the percentage cell viability following incubation with analogs
bearing these functionalities was comparatively lower than compound 5 containing only a simple phenyl
ring.
Table 5. MTT compound toxicity assay data
Compound Ar R1 R2 R3 IC50 (PM) Cell viability
a
(%)
15
1 Ph H H CH2NH2 323±5 42±3
5 Ph H H H n.a.b 93±1
6 Ph H H OMe n.a. 82±1
7 Ph 2-OH H CH2NH2 >100 18±1
8 Ph 3-OH H CH2NH2 >100 50±7
9 Ph 3-F Me CH2NH2 77.1±7.5 11±0
10 Ph 3-F R-Me CH2NH2 85.7±11.8 18±1
11 Ph H iPr CH2NH2 33.5±4.8 50±4
12 Ph H CH2Ph CH2NH2 26.9±4.7 15±1
14 3,5-(CF3)2C6H3 H H CH2NH2 63.9±7.2 8±2
15 C6F5 H H CH2NH2 101±5.7 68±5
16 3-(CF3)C6H4 H H CH2NH2 58.9±9.0 46±5
18 3,5-(CF3)2C6H3 H H H n.a. 76±2
19 C6F5 H H H n.a. 61±3
20 3-(CF3)C6H4 H H H n.a. 27±3
Values shown are mean ± SEM, n   a Data measured at an inhibitor concentration of 100 PM,
percentage inhibition relative to control; b not active.
The cell viability assay results suggested that only compound 15 could be tested further to assess
whether it resulted in cellular BACE1 inhibition; all other compounds were either considered too toxic,
or showed no significant inhibition of BACE1 and were therefore not suitable for further cell-based
testing. Incubation of HEK cells expressing AP-APP and BACE1 with 100 PM of compound 15,
resulted in a 39.4±2.7% inhibition of sAP-APP production, indicating a potentially cell-active
compound. To determine the effects of compound 15 on BACE1 activity specifically, we analyzed the
effect of the compound on HEK cells over-expressing BACE1. The cells were incubated with the
compound, then the conditioned media from these cells was western blotted using a specific sAPPE
16
antibody, 1A9 (see Supporting Information for further details).27 Compound 15 significantly decreased
sAPPE levels in these cells, while sAPPD levels were not significantly altered (Figure 4). These results
suggested that compound 15 significantly inhibited cellular BACE1 activity with little effect on D-
secretase activity, and indicated that compound 15 was a cell-active BACE1 inhibitor.
Figure 4. A) Representative western blot of sAPPD and sAPPE fragments in conditioned media
from HEK 293 cells over-expressing BACE1 incubated for 24 hours with compound 15 at 100 PM. B)
Densitometric analysis of A). Data shown as mean ± SEM, n = 4, **p<0.01.
Tackling compound toxicity
Whilst the presence of the primary amine appeared to be an important feature for the binding of this
series of inhibitors within BACE1, the presence of this functionality resulted in the compounds
exhibiting cell toxicity. We reasoned that this might be owing to the presence of the benzylamine
moiety which is particularly prone to cytochrome P450 metabolism at the methylene position to produce
toxic metabolites such as benzaldehydes in cell media.28, 29 As indicated previously, although the amide
and sulfonamide variants of compound 1 (Figure 1(b), Z = CO and SO2) were predicted to show
favorable binding to BACE1, we were concerned about the solubility of such variants. As an alternative,
we reasoned that conversion of the primary amine into a tertiary amine moiety might reduce the toxicity
associated with this inhibitor series. Interestingly, modeling of the tertiary amine variants of compound
1 within BACE1 indicated that these derivatives may adopt a significantly different binding pose to that
17
predicted for compound 1. The tertiary amine moiety (presumably protonated at physiological pH)
would not be involved in H-bonding contacts to the protein but would instead re-orientate in order to
allow hydrophobic interaction between the N-alkyl groups and the side-chain of Ile126. Additionally,
considerable movement of the core section of the molecule was predicted to result in the formation of
new H-bond contacts involving Thr231 (see Supporting Information).
Four analogs containing tertiary or quaternary amines were synthesized. All these analogs were
shown to be active against BACE1, with compound 22, in particular, attaining an IC50 against BACE1
RI  ȝ0 Table 6). Cell viability of compound 22 was also improved as anticipated (80% cell
YLDELOLW\ DW  ȝ0 FRPSRXQG FRQFHQWUDWLRQ DQG LQ WKH FHOOEDVHG DVVD\ FRPSRXQG 22 (100 PM)
resulted in a 21.7±9.9% inhibition of sAP-APP production. Compound 22 was therefore assessed for
cellular BACE1 inhibition in HEK cells over-expressing BACE1 by western blotting (as described for
compound 15). Compound 22 (100 PM) decreased sAPPE production by 33% compared to control
levels, but this was not statistically significant (p=0.064); sAPPD levels were decreased by 10% (Figure
5).
Table 6. Tertiary and quaternary amine analogs of inhibitor 1 designed to tackle the toxicity
associated with this series of inhibitors.
Compound R1
Inhibition at
100 PM (%) IC50 (PM)
Cell viabilitya
(%)
1 NH2 35.6±1.7 323±5 42±3
21 24.4±7.6 >100 24±1
22 70.1±1.2 63.3±9.1 80±6
18
23 34.4±3.3 >100 38±2
24 44.1±8.7 >100 40±1
Values shown are mean ± SEM, n   a Data measured at an inhibitor concentration of 100 PM,
percentage inhibition relative to control.
Figure 5. A) Representative western blot of sAPPD and sAPPE fragments in conditioned media
from HEK 293 cells over-expressing BACE1 incubated for 24 hours with compound 22 at 100 PM. B)
Densitometric analysis of A). Data shown as mean ± SEM, n = 3.
Chemistry
Preparation of 1 was achieved by firstly protecting 4-(aminomethyl)benzonitrile 25 following the
procedure described by Goodyer et al. to give the Boc-protected amine 26,30 which was reduced using
LiAlH4 to obtain the intermediate 27 in 52% yield over two steps (Scheme 2). The coupling of
4-biphenylacetic acid 28 with 27 delivered 1 in 65% yield using the peptide coupling reagents HOBt
and EDAC. Similarly, compounds 2-6 were readily synthesized by coupling 4-biphenylacetic acid 28
with the respective amine (Scheme 3).
Scheme 2.
19
Reaction conditions: a) (Boc)2O, NEt3, CH2Cl2, 0
oC-rt, 16 h, 95%; b) LiAlH4, THF, 0
oC-rt, 48 h, 55%.
Scheme 3.
Reaction conditions: a) R1-NH2, HOBt, EDAC, NMM, CH2Cl2, 0
oC-rt, 20 h, 42-70%.
The appropriately substituted biaryl acetic acid 33a and 33b, intermediates for compounds 7 and 8
respectively, were prepared according to the general scheme shown in Scheme 4. Methyl 4-bromo-2-
methoxybenzoate 29a was first hydrolyzed to the benzoic acid intermediate 30a, which the
homologation was then achieved following literature procedures described by Aoyama and Cesar to
give methyl 4-bromo-2-methoxyphenylacetate 31a in 62% yield over four steps.31, 32 Subsequent
hydrolysis of 31a, followed by Suzuki coupling of the resultant phenylacetic acid 32a with
phenylboronic acid using tetrabutylammonium bromide (TBAB),33 attained the biaryl scaffold 33a in
50% yield. Similarly, the 3-methoxy-4-phenyl substituted scaffold 33b was obtained following the same
procedure using methyl 4-iodo-3-methoxybenzoate 29b, which the preparation followed the synthetic
route described by Baret et al.34
Scheme 4.
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b,c,d
R2
R1
O
R2
R1
O
29a, 29b R1 = OMe, R2 = X
30a, 30b R1 = OH, R2 = X
a
31a, 31b R1 = OMe, R2 = X
32a, 32b R1 = OH, R2 = X
33a, 33b R1 = OH, R2 = Ph
e
OMe OMe
f
Reaction conditions: a) 10% aq. KOH/MeOH, 90°C, 3 h, 96-98%; b) SOCl2, 60°C, 3 h; c) TMSCHN2,
NEt3, THF/MeCN, 0°C, 24 h; d) PhCO2Ag, NEt3, MeOH, 30 mins; e) 10% aq. KOH/MeOH, 90
oC, 3 h,
16-49%; f) PhB(OH)2, Pd(OAc)2, Na2CO3, TBAB, H2O, 120
oC, microwave, 30-45 mins, 64-89%.
Intermediates 35 and 36 were synthesized from the conversion of 4-biphenylacetic acid 28 to the
methyl ester 34 followed by alkylation at the alpha-C position using procedures reported by Robichaud
et al.35 The alkylated intermediates were subsequently hydrolyzed to give the corresponding
biphenylacetic acid intermediates 35 and 36 (Scheme 5).
Scheme 5.
Reaction conditions: a) MeOH, H2SO4, 65°C, 16 h, 83%; b) KHMDS, THF, 0°C, 20 mins; c) R
2X,
THF, 0°C, 16 h; d) 10% aq. KOH/MeOH, 90°C, 3 h, 36-94%.
Aryl halide intermediates 38 and 39 were prepared by coupling 4-bromophenylacetic acid 37 with
benzylamine and 27 respectively, which the products were coupled to the appropriately substituted aryl
boronic acid under Suzuki coupling conditions to furnish the corresponding biaryl scaffolds.
Compounds 18 and 20 were obtained in 39-41% yields, whereas compounds 14 and 16 were obtained in
46-52% yields after deprotection using TFA (Scheme 6). Similarly, compound 17 was obtained from
the deprotection of 40 using BBr3 (Scheme 7).
Scheme 6.
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Reaction conditions: a) PhCH2NH2 or 27, HOBt, EDAC, NMM, CH2Cl2, 0
oC-rt, 20 h, 65-81%; b)
R2B(OH)2, Pd(OAc)2, PPh3, K2CO3, toluene, 120
oC, microwave, 30-45 mins, 49-95%; c) TFA, CH2Cl2,
0°C, 2-3 h, 75-95%.
Scheme 7.
Reaction conditions: a) 4-(MeO)C6H4B(OH)2, Pd(OAc)2, PPh3, K2CO3, toluene, 120
oC, microwave,
30-45 mins, 84%; b) BBr3, CH2Cl2, rt, 16 h, 66%.
Synthesis of the pentafluorophenyl analog 19 involved initially the hydrolysis of
4-cyanomethylphenylboronic acid 41, following the procedure described by Serafin and Makosza.36
Subsequent Suzuki coupling of 42 with pentafluorophenylbromide furnished 43, which was then
coupled with benzylamine to give compound 19 in 14% yield over three steps (Scheme 8).
Scheme 8.
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Reaction conditions: a) 20% aq. KOH, 100oC, 2 h, 87%; b) C6F5Br, Pd(OAc)2, Na2CO3, TBAB, H2O,
120oC, microwave, 30-45 mins, 39%; c) PhCH2NH2, HOBt, EDAC, NMM, CH2Cl2, 0
oC-rt, 20 h, 40%.
Alkylation of 1 using the conditions reported by Ju and Varma37 afforded compounds 21-24 in
moderate yields (Scheme 9).
Scheme 9.
Reaction conditions: a) K2CO3, H2O, 120
oC, microwave, 20 mins, 34-53%.
Table 7 summarizes the synthesis of compounds 1, 7-12, and 15 from the respective intermediates
described above using a two-step coupling-deprotection method.
Table 7 Synthesis of compounds 1, 7-12, and 15.
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Compound Intermediate Ar R1 R2
Deprotection
methodb
Yield (%)
1 28 Ph H H 1 65
7 33a Ph 2-OH H 2 83
8 33b Ph 3-OH H 2 59
9 c.s.a Ph 3-F Me 1 71
10 c.s.a Ph 3-F R-Me 1 79
11 35 Ph H iPr 1 75
12 36 Ph H CH2Ph 1 68
15 43 C6F5 H H 1 77
a commercial source; b Reaction conditions: Method 1) TFA, CH2Cl2, 0°C, 2-3 h; Method 2) BBr3,
CH2Cl2, rt, 16 h.
Conclusions
We have successfully used the structure-based molecular design program SPROUT to develop a new
BACE1 inhibitor scaffold using a de novo fragment-based ligand design approach. Based upon a simple
biphenylacetamide core structure, an SAR study around the designed ligand was conducted which
confirmed that the amine functionality was essential for BACE1 inhibition. The binding affinity of the
initial designed skeleton was enhanced, from an initial IC50DJDLQVW%$&(RIȝ0WRȝ0IRU
one of the most potent inhibitors, using a recently developed in silico optimization software SPROUT-
HitOpt. Subsequent cell viability assays revealed significant toxicity associated with the majority of
compounds within this series of inhibitors. However, we were able to demonstrate that compound 15,
with a relatively low toxicity, was a cell-active BACE1 inhibitor which selectively inhibited cellular
BACE1 activity with little effect on D-secretase activity. Although the toxicity associated with this
series of compounds has rendered them unsuitable for further studies in in vivo experiments, we have
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demonstrated the successful application of SPROUT and SPROUT-HitOpt in the development of a
small-molecule non-peptidic inhibitor against an enzyme that is a challenging therapeutic target.
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